Experimental cell therapy tested as last hope for rare cancers
Disease control
Terminated
This study tested an experimental cell therapy called brexucabtagene autoleucel in adults with rare and aggressive types of B-cell blood cancers that had returned or stopped responding to standard treatments. The therapy, known as CAR-T, involves genetically modifying a patient's…
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC